1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Placebo - 50 mg: new trials by email Literature Review of Placebo - 50 mg trials Research Report on Placebo - 50 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg - Chronic Spontaneous Urticaria | Phase 2 | Recruiting | Pfizer | 200 | 2025-10-30 | 2026-10-26 |
Chronic Urticaria (1) · Pruritus (1) · Urticaria (1)
Pfizer (1)
Bulgaria (1) · Canada (1) · China (1) · Germany (1) · Japan (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · United States (1)
2025 (1)